Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib plus venetoclax vs chlorambucil plus obinutuzumab in first-line CLL/SLL
2023-503469-49-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of ibrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free survival. Planned start Oct 2023; status: authorised.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2023-503469-49-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503469-49-00.